Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease

Journal of Crohn's and Colitis

Volumn 5, Issue 3, 2011, Pages 222-226

  Levine, Arie ^a   Turner, Dan ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antibiotics; Apoptosis; Azithromycin; Child; Crohn's disease; Inflammatory bowel disease; Therapy

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; IMMUNOMODULATING AGENT; METRONIDAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; BIOFILM; CLINICAL ARTICLE; COLON DISEASE; CONTROLLED STUDY; CROHN DISEASE; DERMATITIS; DIARRHEA; DRUG WITHDRAWAL; ENTEROPATHY; FEMALE; HUMAN; MALE; PEDIATRICS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REMISSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZITHROMYCIN; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HUMANS; MALE; METRONIDAZOLE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955950438     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.01.006     Document Type: Article

References (33)

1. Sartor J.B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997, 92:S5-S11.
2. Martin H.M., Campbell B.J., Hart C.A., Mpofu C., Nayar M., Singh R., et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004 Jul, 127(1):80-93.
3. Ryan P., Kelly R.G., Lee G., et al. Bacterial DNA within granulomas of patients with Crohn's disease - detection by laser capture microdissection and PCR. Am J Gastroenterol 2004 Aug, 99(8):1539-1543.
4. Mow W.S., Landers C.J., Steinhart A.H., et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. Dig Dis Sci 2004, 49:1280-1286.
5. Glasser A.L., Boudeau J., Branch N., Perruchot M.H., Colombel J.F., Darfeuille-Michaud A. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001 Sep, 69(9):5529-5537.
6. Bringer M.A., Glasser A.L., Tung C.H., Meresse S., Darfeuille-Michaud A. The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell Microbiol 2006, 8:471-484.
7. Martinez-Medina M., Naves P., Blanco J., et al. Biofilm formation as a novel phenotypic feature of adherent-invasive Escherichia coli (AIEC). BMC Microbiol 2009, 21(9):202.
8. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Investig 2004, 113:1296-1306.
9. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 May 31, 411(6837):599-603.
10. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 May 31, 411(6837):603-606.
11. Barrett J.C., Hansoul S., Nicolae D.L., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962.
12. Zelinkova Z., Van Beelen A.J., Dekort S., et al. Muramyl dipeptide-induced gene expression in NOD2 mutant and wild type Crohn's disease patient-derived dendritic cells. Inflamm Bowel Dis 2008, 14:186-194.
13. Rioux J.D., Xavier R.J., Taylor K.D., et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007, 39:596-604.
14. Kuballa P., Huett A., Rioux J.D., Daly M.J., Xavier R.J. Impaired autophagy of an intracellular pathogen induced by a Crohn's disease associated ATG16L1 variant. PLoS ONE 2008, 3(10):e3391.
15. Wehkamp J., Harder J., Weichenthal M., et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal {alpha}-defensin expression. Gut 2004 Nov, 53(11):1658-1664.
16. Ina K., Itoh J., Fukushima K., et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999, 163:1081-1090.
17. Colombel J.F., Lemann M., Cassagnou M., et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999 Mar, 94(3):674-678.
18. Steinhart A.H., Feagan B.G., Wong C.J., Vandervoort M., Mikolainis S., Croitoru K., et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002, 123:33-40.
19. Sandborn W.J., Feagan B.G., Lichtenstein G.R. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007, 26:987-1003.
20. Travis S.P.L., Stange E.F., Lemann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease:current management. Gut 2006, 55:6-35.
21. Kadota J., Mizunoe S., Kishi K., Tokimatsu I., Nagai H., Nasu M. Antibiotic-induced apoptosis in human activated peripheral lymphocytes. Int J Antimicrob Agents 2005, 25 Mar(3):216-220.
22. Mizunoe S., Kadota J., Tokimatsu I., Kishi K., Nagai H., Nasu M. Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. Int Immunopharmacol 2004 Sep, 4(9):1201-1207.
23. Culic O., Erakovic V., Cepelak I., Barisic K., Brajsa K., Ferencic Z., et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002 Aug 30, 450(3):277-289.
24. Bousvaros A., Antonioli D.A., Colletti R.B., et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007 May, 44(5):653-674.
25. Satsangi J., Silverberg M., Vermiere S., Colombel J.F. The Montreal classification of inflammatory bowel diseases; controversies, consensus and implications. Gut 2006, 55:749-753.
26. Turner D., Griffiths A.M., Walters T.D., et al. Appraisal of the Pediatric Crohn's Disease Activity Index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol 2010, 105:2085-2092.
27. Vernier-Massouille G., Balde M., Salleron J., et al. Natural history of pediatric Crohn's disease: a population based study. Gastroenterology 2008, 135:1106-1113.
28. Prantera C., Lochs H., Campieri M., et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006 Apr 15, 23(8):1117-1125.
29. Luke D.R., Foulds G. Disposition of oral azithromycin in humans. Clin Pharmacol Ther 1997, 61(6):641-648.
30. Subramanian S., Roberts C., Hart C.A., et al. Replication of colonic Crohn's disease mucosal Escherichia coli isolates within macrophages and their susceptibility to antibiotics. Antimicrob Agents Chemother 2008 February, 52(2):427-434.
31. Saiman L., Anstead M., Mayer-Hamblett N., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010 May 5, 303(17):1707-1715.
32. Southern K.W., Barker P.M., Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004, 2:CD002203.
33. Kabra S.K., Pawaiya R., Lodha R., et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. J Cyst Fibros 2010 Jan, 9(1):17-23.